2 misunderstood stocks?

These two companies have put their foot in it with investors, but is this justified?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Now and again, otherwise sophisticated companies make a blunder with unexpected announcements and then worsen it with inadequate or no clarification. Here are two recent examples.

Integrated Research (ASX: IRI) is a Sydney-based company involved in the design, development and implementation of management reporting software specific to large enterprises and unified communications networks. Its major software suite is Prognosis, which has achieved significant international acceptance, particularly in the US. The list of customers reads like the Forbes 100, and Integrated Research has all the characteristics of a progressive company.

That was all well and good, until a paltry announcement on 27 August stated that CEO Mark Brayan was leaving his position that day and would be replaced by Darc Rasmussen, effective on 8 October 2013.

What should investors make of this? Uninformed speculation is pointless, and this Fool reacts by again checking the 2013 accounts. Integrated Research remains debt-free, has a 30% return on equity, good operational cash flow, expenses research and development, and exercises good cost controls – in short, it is a well run company. On 31 July 2013, cash in the bank stood at $18.1 million.

In 2013 Americas revenue was up 6.4%, however both Asia Pacific (down 13.5%) and Europe (down 3.6%) were disappointing. The Americas share of total revenue was 72%.

Perhaps the above is the key to the abrupt change in top management. Mr Rasmussen is a very experienced global executive with the credentials to move Integrated Research into the next stage of growth – especially in Asia and Europe. It has to be acknowledged that Mr Brayan's tenure was extremely productive for both the company and shareholders.

Given this, the thesis for investing in Integrated Research remains valid – it is a successful company with 2013 price earnings of 19, a strong balance sheet and good cash flow. Most importantly, it is involved in a high growth segment of the global IT industry.

Metcash (ASX: MTS) is a wholesale distribution business with divisions specialising in grocery, fresh produce, hardware, liquor and automotive parts and accessories (75% owned). Well known outlets include Mitre 10 and IGA.

The 'surprise in a box' was the revelation of a "high single digit" 2014 profit downgrade, just weeks after presenting the 2013 results. Needless to say, the share price fell sharply and hasn't done much since. Is there something fundamentally wrong with the Metcash strategy?

The retail partners of Metcash have to compete with Coles and Woolworths if they want to stay in business. As a wholesaler, Metcash just doesn't have the buying power to supply them at reasonable margins. What's worse, Metcash duplicates functions by having both national and state buying facilities! Unless it does something about this, it is doomed to be an inefficient business.

Its 2012 results were impacted by impairment and restructuring costs associated with the Franklins purchase (a disaster). As a result of this and the need for capital, an equity raising was undertaken. Part of this was used for Project Mustang, an advanced warehouse facility. Mustang is one step to productivity improvements.

The company has had a fairly uninspiring recent history, however the new CEO may have plans to refine the business and produce earnings growth. As yet, shareholders simply don't know.

Foolish takeaway

Integrated Research is a high margin business in an ongoing growth cycle whereas Metcash is a low margin business attempting to hold its position. At 95c, Integrated Research is selling at 13.6 times projected 2014 earnings (7c per share) and a partly franked yield of 5%. By comparison Metcash ($3.22) is selling at 11.5 times estimated 2014 earnings and a 7.5% fully franked yield. Although income investors may prefer Metcash, Integrated Research has the better growth prospects.

Want even more stock ideas? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014

More reading


Motley Fool contributor Peter Andersen owns shares in Integrated Research.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »